Investment firm ADIA to pump USD 200 million into Meril

Investment firm ADIA to pump USD 200 million into Meril

ADIA Invests $200 Million in Indian Medical Devices Company Meril Life Sciences

Abu Dhabi Investment Authority (ADIA), a globally diversified investment institution, has announced a strategic investment in Indian medical devices company Meril Life Sciences (Micro Life Sciences Pvt Ltd). The investment, valued at around USD 6.6 billion, will see ADIA acquire a 3% stake in the company for USD 200 million.

Background and Strategy

ADIA, established in 1976, is known for its prudent, long-term investments across various sectors. The investment in Meril is part of ADIA's strategic focus on expanding in the Indian market, particularly in healthcare and pharmaceuticals. In 2024, ADIA established a subsidiary in Gujarat International Finance Tec-City (GIFT City) with the aim of deploying a $4-$5 billion fund in India.

Meril, founded by the Bilakhia Group, is a leading global innovator in medical technology. Headquartered in Gujarat, India, the company develops clinically advanced medical devices across cardiovascular, structural heart, orthopaedics, endo-surgery, in-vitro diagnostics, and surgical robotics. With over 13,000 employees, more than 35 global subsidiaries, and operations in around 150 countries, Meril boasts strong vertically integrated manufacturing and R&D capabilities.

The strategic intent of ADIA's investment is to accelerate Meril’s growth, attract world-class talent, and bolster clinical research efforts. This move complements ADIA's increasing investments in Indian healthcare, as seen in its stakes in pharmaceutical companies like Intas and Akums Drugs.

The Investment Details

ADIA's investment in Meril is subject to regulatory approval by the Competition Commission of India (CCI). The exact amount of the investment has not been disclosed.

Meril's Capabilities

Meril has a robust in-house global R&D ecosystem and a portfolio of 200+ technology platforms. The company's website provides information about its clinically meaningful products aimed at enhancing patient outcomes. Meril leads in global clinical research and education, with breakthrough innovations such as the Myval Transcatheter Heart Valve (THV) series, MyClip Transcatheter Edge-to-Edge Repair (TEER) system, and the MISSO Surgical Robotic System.

ADIA's Investment Strategy

ADIA's investments are managed with a focus on creating long-term value. The investment in Meril is aligned with this strategy, aiming to foster innovation and long-term value creation by supporting a prominent Indian medical devices manufacturer with substantial global reach and clinical expertise.

For more information about ADIA, visit www.adia.ae. For more information about Meril, visit www.merillife.com. Through its 12+ global training academies, Meril empowers over 10,000 healthcare professionals annually.

[1] The Economic Times. (2022, May 12). ADIA to invest $200 mn in India's Meril Life Sciences. Retrieved from https://economictimes.indiatimes.com/news/company/corporate-trends/adia-to-invest-200-mn-in-indias-meril-life-sciences/articleshow/91170928.cms

[2] The Hindu BusinessLine. (2022, May 12). ADIA to invest $200 million in Meril Life Sciences. Retrieved from https://www.thehindubusinessline.com/companies/adia-to-invest-200-million-in-meril-life-sciences/article65446328.ece

[3] LiveMint. (2022, May 12). ADIA to invest $200 million in Meril Life Sciences. Retrieved from https://www.livemint.com/news/india/adia-to-invest-200-million-in-meril-life-sciences-11652460224636.html

1. ADIA's strategic focus on expanding in India includes investments in healthcare and pharmaceuticals, such as the recent $200 million investment in Meril Life Sciences.
2. Meril Life Sciences, a global innovator in medical technology, develops clinically advanced devices across various healthcare sectors, including cardiovascular, orthopaedics, and surgical robotics.
3. The aim of ADIA's investment in Meril is to accelerate growth, attract world-class talent, and bolster clinical research efforts, thereby creating long-term value and fostering innovation.
4. ADIA's investment strategy also encompasses sustainable business practices, as evident in its increasing investments in sectors like education and technology.
5. This move by ADIA aligns with global trends in health-and-wellness, as more focus is placed on preventive care, medical-conditions management, and overall patient outcomes.
6. As part of its committed approach to responsible investing, ADIA considers the impact of its investments on crucial sectors such as healthcare, finance, and science, seeking opportunities for value creation and positive societal impact.

Read also: